NCT03363763: A trial that was reported late by Aucta Pharmaceuticals, Inc
This trial has reported, although it was 443 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03363763 |
|---|---|
| Title | Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 12, 2017 |
| Completion date | March 24, 2023 |
| Required reporting date | March 23, 2024, midnight |
| Actual reporting date | June 10, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 443 |